Gsk Consumer

ICICI Direct recommended hold rating on GSK Consumer with a target price of Rs 8340 in its research report dated August 05, 2019.

GSK Consumer Q1 PAT seen up 15.6% YoY to Rs. 231.8 cr: ICICI Direct

Net Sales are expected to increase by 9.2 percent Y-o-Y (down 6 percent Q-o-Q) to Rs. 1,208.5 crore, according to ICICI Direct.

Buy GSK Consumer; target of Rs 8340: ICICI Direct

ICICI Direct is bullish on GSK Consumer has recommended buy rating on the stock with a target price of Rs 8340 in its research report dated May 13, 2019.

GSK Consumer Q4 PAT seen up 10.1% YoY to Rs. 233.1 cr: ICICI Direct

Net Sales are expected to increase by 9.8 percent Y-o-Y (up 16 percent Q-o-Q) to Rs. 1,295.4 crore, according to ICICI Direct.

GSK Consumer Q4 PAT seen up 15.7% YoY to Rs. 245.1 cr: Kotak

Net Sales are expected to increase by 11.7 percent Y-o-Y (up 18 percent Q-o-Q) to Rs. 1,317.6 crore, according to Kotak.

GSK Consumer Q3 PAT seen up 11.7% YoY to Rs. 182.8 cr: Kotak

Net Sales are expected to increase by 7.1 percent Y-o-Y (down 12.6 percent Q-o-Q) to Rs. 1,111.6 crore, according to Kotak.

Buy GSK Consumer; target of Rs 8000: ICICI Direct

ICICI Direct is bullish on GSK Consumer has recommended buy rating on the stock with a target price of Rs 8000 in its research report dated November 05, 2018.

GSK Consumer Q2 PAT seen up 7.4% YoY to Rs. 206.7 cr: ICICI Direct

Net Sales are expected to increase by 8.7 percent Y-o-Y (up 13.4 percent Q-o-Q) to Rs. 1,212.4 crore, according to ICICI Direct.

GSK Consumer Q1 PAT seen up 34.4% YoY to Rs. 177.7 cr: ICICI Direct

Net Sales are expected to increase by 8.5 percent Y-o-Y (down 9.4 percent Q-o-Q) to Rs. 1,068.7 crore, according to ICICI Direct.

Horlicks: A potential nutrient fit for select FMCG giants

While the category itself undergoes a change, even the existing business of GSK Consumer holds value for other FMCG players and there is a scope for operational synergies

GSK Consumer Q4 PAT seen up 6.7% YoY to Rs. 187.6 cr: ICICI Direct

Net Sales are expected to increase by 1.8 percent Y-o-Y (up 2.5 percent Q-o-Q) to Rs. 1,060.1 crore, according to ICICI Direct.

GSK Consumer Q4 PAT seen up 10.1% YoY to Rs. 193.6 cr: Prabhudas Lilladher

Net Sales are expected to increase by 9 percent Y-o-Y (up 16.1 percent Q-o-Q) to Rs. 1201 crore, according to Prabhudas Lilladher.

Likely GST cut in few items pushes GSK Consumer up 3.5%; Nomura maintains buy

It believes that a potential reduction in GST rates for malted food drink is a short-term catalyst and it could drive penetration-led growth.

Buy GSK Consumer; target of Rs 5960: ICICI Direct

ICICI Direct recommended buy rating on GSK Consumer with a target price of Rs 5960 in its research report dated August 11, 2017.

Buy GSK Consumer; target of Rs 6025: Axis Direct

AxisDirect' is bullish on GSK Consumer has recommended buy rating on the stock with a target price of Rs 6025 in its research report dated July 24, 2017.

Sell GSK Consumer; target of Rs 4380: Motilal Oswal

Motilal Oswal is bearish on GSK Consumer has recommended sell rating on the stock with a target price of Rs 4380 in its research report dated May 12, 2017.

Buy GSK Consumer; target of Rs 6075: ICICI Direct

ICICI Direct is bullish on GSK Consumer has recommended buy rating on the stock with a target price of Rs 6075 in its research report dated May 12, 2017.

Buy, sell, hold: 9 stocks & 2 sectors to focus as market hits record high

CLSA says HDFC remains its top pick in financials segment as the expansion of subsidy scheme by government is positive for housing finance companies.

Accumulate GSK Consumer; target of Rs 6200: Emkay

Emkay is bullish on GSK Consumer has recommended accumulate rating on the stock with a target price of Rs 6200 in its research report dated May 19, 2016.

Novartis India up 3% on FIPB nod to transfer OTC division

After the approval from board of directors and FIPB, the company and GSK will proceed with completing documentation required to complete this transaction, it said.

FMCG - Elephant trails moving towards Urban paths: Emkay

Emkay Global Financial Services has come out with its report on FMCG sector. "Based on urban revival and category preference, our top picks in the consumer staples space are Britannia, Colgate, GSK Consumer, Nestle, Dabur & Godrej Consumer, while top avoids are Emami, HUL & Marico", says Emkay.

Stocks in news: Sun Pharma, Gitanjali, Tata Motors, Winsome

HDIL | Sun Pharma | Tata Chemicals | Winsome Diamonds | Glenmark Pharma | Gitanjali Gems | Jet Airways | Coal India | Financial Technologies | HT Media | Bajaj Auto | United Breweries | Tata Motors and Ashok Leyland are stocks, which are in the news today.

Stocks in news: Spicejet, UB, Mangalore Chem, ING Vysya

Spicejet | Reliance Power | United Breweries | Glenmark Pharma | GSK Consumer | Jet Airways | Unitech | Mangalore Chemical | Deepak Fertiliser | ING Vysya Bank | DLF | IOC | Kingfisher Airlines | MphasiS | Garware Wall | Lupin and Alstom T&D are stocks, which are in the news today.

Standard Chartered downgrades GSK Consumer, shares slip

Standard Chartered feels the maker of Boost and Horlicks will see lower volume growth in health food drinks and earnings growth over three years will also be limited due to continuing high advertising spends.

GSK Consumer Healthcare Q2 net profit up 13% to Rs 120cr

The company's net sales in April-June were up 17 percent to Rs 853 crore.